Indications and Usage Mechanisms of Action Pharmacokinetics Clinical Research
ChemicalBook > CAS DataBase List > Valsartan

Valsartan

Indications and Usage Mechanisms of Action Pharmacokinetics Clinical Research
Product Name
Valsartan
CAS No.
137862-53-4
Chemical Name
Valsartan
Synonyms
Nisis;Tareg;DIOVAN;CGP-48933;VALSARTAN;Valsratan;Valsatarn;Varsartan;Valsartane;L-Valsartan
CBNumber
CB6182539
Molecular Formula
C24H29N5O3
Formula Weight
435.52
MOL File
137862-53-4.mol
More
Less

Valsartan Property

Melting point:
116-117°C
Boiling point:
684.9±65.0 °C(Predicted)
Density 
1.212±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO: ≥20mg/mL
pka
3.56±0.10(Predicted)
form 
powder
color 
white to tan
optical activity
[α]/D -55 to -70°, c = 1 in methanol
Water Solubility 
84.99mg/L(25 ºC)
Merck 
14,9916
Stability:
Hygroscopic
InChIKey
ACWBQPMHZXGDFX-QFIPXVFZSA-N
CAS DataBase Reference
137862-53-4(CAS DataBase Reference)
EPA Substance Registry System
L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (137862-53-4)
More
Less

Safety

Hazard Codes 
Xi
Risk Statements 
36/37/38
Safety Statements 
26-37/39
WGK Germany 
3
RTECS 
YV9455000
HS Code 
29339900
Hazardous Substances Data
137862-53-4(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
PHR1315
Product name
Valsartan
Purity
Pharmaceutical Secondary Standard; Certified Reference Material
Packaging
1g
Price
$72.8
Updated
2021/03/22
Sigma-Aldrich
Product number
Y0001132
Product name
Valsartan
Purity
European Pharmacopoeia (EP) Reference Standard
Price
$190
Updated
2021/03/22
Sigma-Aldrich
Product number
1708762
Product name
Valsartan
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
350mg
Price
$366
Updated
2021/03/22
TCI Chemical
Product number
V0112
Product name
Valsartan
Purity
>98.0%(HPLC)(T)
Packaging
1g
Price
$52
Updated
2021/03/22
TCI Chemical
Product number
V0112
Product name
Valsartan
Purity
>98.0%(HPLC)(T)
Packaging
5g
Price
$173
Updated
2021/03/22
More
Less

Valsartan Chemical Properties,Usage,Production

Indications and Usage

Valsartan is a type of specific angiotensin I (AT1) receptor antagonist and a clinical non-dermal AT1 receptor antagonist following losartan that has important effects in adjusting bodily blood pressure and maintaining electrolyte-body fluid balance. Valsartan’s antihypertensive effects are stronger than those of enalapril and is suitable for treating hypertension, mild to moderate primary hypertension, and especially secondary hypertension caused by renal damage. It can significantly reduce proteinuria for hypertension patients with diabetes or normal liver functions, and it can promote uric acid and urinary sodium to protect the kidney. Valsartan is also suitable for reducing the cardiovascular mortality for high risk patients (left ventricular failure or dysfunction) after experiencing a heart attack.

Mechanisms of Action

Valsartan selectively affects the AT1 receptor subtype and prevents AT1 from binding with AT1 receptors (its selective AT1 receptor antagonizing effect is about 20000 times greater than its effects on AT2 receptors), thus inhibiting vasoconstriction and aldosterone release, producing an antihypertensive effect, but it cannot inhibit the release of aldosterone caused by potassium ions (K+). Valsartan does not affect angiotensin-converting enzymes (ACE) or renin and its receptors, and it does not inhibit ion channels related to blood pressure regulation and sodium balance. Valsartan does not inhibit ACE and does not affect bodily bradykinin levels, thus causing less coughing side effects than ACE inhibitors. Valsartan does not affect heart rate when lowering blood pressure. Sudden ceasing in Valsartan use will not cause rebound hypertension or other side effects. Valsartan does not affect hypertension patients’ overall cholesterol, triglyceride, blood glucose, or uric acid levels.

Pharmacokinetics

For most patients, a single oral dose will have antihypertensive effects that occur within 2 hours, peak at 4-6 hours, and continue for over 24 hours. 2-4 weeks of treatment will result in maximum hypertensive curative effects, which will last throughout long-term treatment. It can be used with thiazide diuretics to further strengthen antihypertensive effects.

Clinical Research

A clinical trial showed that Valsartan has very noticeable effects on mild to moderate hypertension. A daily dose of ≥80 mg can effectively control systolic and diastolic blood pressure while not affecting blood pressure’s circadian rhythm; a daily 160mg dose has more noticeable effects than a daily 100mg dose of losartan. Moderate hypertension patients with intact renal functions have a good tolerance towards Valsartan, Valsartan’s curative effects are significantly superior to those of ACE inhibitors, and there are minimal adverse reactions. Effective in treating severe hypertension when combined with other antihypertensive drugs.

Description

Diovan was launched in Germany and the UK as an angiotensin Ⅱ antagonist for use as an antihypertensive agent. Biphenylbromomethyl nitrite serves as the starting material for a three step synthesis of the compound, in which the (S)- enantiomer is more active than the (R)-enantiomer. Valsartan is a nonpeptide drug which is a highly specific antagonist of the AT1 receptor and is potent and orally active. This receptor is responsible for angiotensin Ⅱ cardiovascular effects (aldosterone and catecholamine secretion, vascular constriction, positive inotropic response and renal effects). Unlike losartan, it is not a prodrug and a single daily dose is comparible in activity to the ACE drug enalapril. It also did not exhibit the coughing side effect observed with ACE inhibitors. Diovan is slowly metabolized (long lasting) with its main metabolite being significantly less active. There was no evidence of rebound hypertension when drug treatment was terminated and was as effective as the dihydropyridine Ca antagonist anlodipine.

Chemical Properties

White Crystalline Powder

Originator

Norvartis (Switzerland)

Uses

A nonpeptide angiotensin II AT1-receptor antagonist. Antihypertensive.

Uses

Angiotensin II inhibitor, antihypertensive

Uses

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second l

Definition

ChEBI: A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.

Manufacturing Process

0.5 g of 2'-cyanobiphenyl-4-carbaldehyde, 2.5 g of molecular sieve 5 A in tetrahydrofuran with stirring at room temperature for 36 hours; then the reaction mixture was cooled to 0°-5°C, 0.815 g of (L)-valine methyl ester hydrochloride and 180 mg of sodium cyanoborohydride dissolved in 4.8 ml of methanol are added. The mixture is stirred at room temperature for 24 hours and then concentrated in vacuo yields N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)- valine methyl ester after flash chromatography.
1.15 g of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester, 0.625 ml of triethylamine in 9 ml of dichloromethane are treated 0.56 ml of n-valeryl chloride at 0°C and stirred at room temperature overnight and then evaporated to dryness. The residue is taken up in diethyl ether and the diethyl ether mixture is washed with sodium hydrogencarbonate solution and brine.
Flash chromatography (180 g of silica gel; ethyl acetate/petroleum ether 1:1) yields N-valeryl-N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester. (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5- yl)biphenyl-4-ylmethyl]-amine. The product can be prepared starting from 1.40 g of N-valeryl-N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester and 2.25 g of tributyltin azide with subsequent flash chromatography; melting interval 105°-115°C (from ethyl acetate).

brand name

Diovan (Novartis).

Therapeutic Function

Antihypertensive

General Description

Valsartan, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (Diovan), likelosartan, possesses the acidic tetrazole system, which mostlikely plays a role, similar to that of the acidic groups of angiotensinII, in binding to the angiotensin II receptor. In addition,the biphenyl system that serves to separate the tetrazolefrom the aliphatic nitrogen is still present. In addition, there isa carboxylic acid side chain in the valine moiety that alsoserves to bind to the angiotensin II receptor.

Valsartan Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Valsartan Suppliers

Labex Corporation
Tel
+91-11-26135922 or +91-11-46160359
Fax
+91-11-26124735
Email
labex@labex.net
Country
India
ProdList
392
Advantage
55
Clearsynth Labs Limited
Tel
+91-22-26355700
Fax
+91-22-26355701
Email
info@clearsynth.com
Country
India
ProdList
9708
Advantage
58
Jai Radhe Sales
Tel
+(91)-(79)-26431096/65255722
Fax
+(91)-(79)-26569884
Email
info@jairadhesales.com
Country
India
ProdList
397
Advantage
60
More
Less

View Lastest Price from Valsartan manufacturers

Hangzhou Huarong Pharm Co., Ltd.
Product
Valsartan 137862-53-4
Price
US $0.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
1000KG
Release date
2021-09-16
Hebei Lingding Biological Technology Co., Ltd
Product
Valsartan 137862-53-4
Price
US $100.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
9000kg/per week
Release date
2021-09-01
Wuhan Monad Medicine Tech Co.,LTD
Product
Valsartan 137862-53-4
Price
US $10.00/KG
Min. Order
25Kg/Drum
Purity
99.99%
Supply Ability
20 tons/month
Release date
2021-04-19

137862-53-4, ValsartanRelated Search:


  • L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
  • Ambroxol Hydrochloride Imp.D
  • 3-Methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic aci
  • (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]amine
  • (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic aci
  • VALSARTAN IMP C
  • Valsartan,99%e.e.
  • N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE
  • VALSARTAN
  • CGP-48933
  • DIOVAN
  • VALSARTAN, MM STANDARD
  • VALSARTAN, USP STANDARD
  • VALSARTAN, RELATED COMPOUND A(R)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE USP STANDARD
  • VALSARTAN, RELATED COMPOUND C(S)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE BENZYL ESTER USP STANDARD
  • Valsartan99%
  • N-[[(2-Cyano(1.1-Biphenyl)-4-Yl)Methyl]MethylEster]-L-Valine.Hydrochloride
  • ValsartanC24H29N503
  • Valsartane
  • Valsratan
  • (S)-2-(N-((2''-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID
  • Diovan, N-(1-Oxopentyl)-N-[[2(1H-tetrazol-5-yl)[1,1biphenyl]-4-yl]methyl]-L-valine, CGP-48933
  • N-(1-N.PENTANOYL)-N-[[2''-(1H-TETRAZOL-5-YL)[1'',1- BIPHENYL]-4-YL]METHYL]-L-VALINE/VALSARTAN
  • L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
  • Nisis
  • Tareg
  • 3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic acid
  • Valsartan Related Compound A (10 mg) ((R)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine)
  • N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-
  • N-(1-Oxopentyl)-N-[[2’-(1H-tetrazol-5-y1)[1,1'-biphenyl]-4-y1]methyl]-L-valine
  • N-(1-Oxopentyl)-N-[[2'-(2H-tetrazo-5-yl)
  • Valsartan (350 mg)G0F0650.997mg/mg(an)
  • Valsartan (350 mg)
  • 3-Methyl-2-[pentanoy
  • L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
  • (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)pentanaMido)-3-Methylbutanoic acid
  • Valsartan API
  • Valsartan (>99% pure)
  • N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
  • (2S)-3-Methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}Methyl)pentanaMido]butanoic acid
  • L-Valsartan
  • 2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)pentanaMido)-3-Methylbutanoic acid
  • ((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-L-valine
  • N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
  • <br>(S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3 -methylbutanoic acid
  • (S)-N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine
  • (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
  • Valsartan, 99%, a nonpeptide angiotensin II AT1 receptor antagonist
  • Valsartan 3-Methyl-2-[pentanoyl-[[4- [2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl] amino]-butanoic acid
  • Valsartan Manufacturer
  • (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
  • Valsatarn
  • Valsartan Impurity 18
  • (S)-2-(N-((2'-(1H-tetrazol-5-yl)
  • Valsartan CRS
  • Valsartan RS
  • Valsartan for peak identification CRS
  • Valsartan for system suitability CRS